Fahd Rahman, MD
Hematology & Oncology · Elkton, MDNPI 1518165943
Payments from drug & device makers
Across 60 payments — averaging $23.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$211
- ADC Therapeutics America, Inc.$125
- Daiichi Sankyo Inc.$114
- E.r. Squibb & Sons, L.L.C.$97
- Gilead$96
- Pfizer$84
- plus $701 from 23 others
What the payments were for
- Food & beverage$1,15481%
- Education$27419%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $211 |
| ADC Therapeutics America, Inc. | 1 | $125 |
| Daiichi Sankyo Inc. | 3 | $114 |
| E.r. Squibb & Sons, L.L.C. | 5 | $97 |
| Gilead | 4 | $96 |
| Pfizer | 6 | $84 |
| Stemline Therapeutics Inc. | 2 | $83 |
| Merck | 4 | $82 |
| GSK | 3 | $69 |
| Seagen Inc. | 3 | $55 |
| Regeneron Healthcare Solutions, Inc. | 1 | $42 |
| Eisai Inc. | 2 | $41 |
| Johnson & Johnson(2 entities) | 2 | $34 |
| Tesaro, Inc. | 1 | $32 |
| Novartis | 2 | $29 |
| AbbVie | 1 | $21 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Amgen | 1 | $21 |
| Beigene USA, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| EMD Serono, Inc. | 1 | $19 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Bristol Myers Squibb | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Partner Therapeutics, Inc. | 1 | $14 |
| Incyte Corporation | 1 | $12 |
| AMAG Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$1,427 in reported general payments places this provider in the 30th percentile of 242 hematology & oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 41 | $707,949 |
| PromactaEltrombopag Olamine | 27 | $385,176 |
| ImbruvicaIbrutinib | 20 | $325,241 |
| DopteletAvatrombopag Maleate | 12 | $284,507 |
| Lenalidomide | 25 | $281,594 |
| PomalystPomalidomide | 12 | $280,767 |
| EliquisApixaban | 219 | $241,035 |
| TagrissoOsimertinib Mesylate | 13 | $234,329 |
| CalquenceAcalabrutinib Maleate | 13 | $196,371 |
| XareltoRivaroxaban | 138 | $150,061 |
| ProcritEpoetin Alfa | 31 | $80,901 |
| NplateRomiplostim | 12 | $60,759 |
| Abiraterone Acetate | 11 | $53,403 |
| Sunitinib Malate | 13 | $27,878 |
| RetacritEpoetin Alfa-Epbx | 13 | $6,048 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $12 | $707,94941 claims |
| AstraZenecaTagrisso, Calquence | $211 | $430,70026 claims |
| NovartisPromacta | $29 | $385,17627 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $97 | $280,76712 claims |
| PfizerEliquis, Retacrit | $84 | $247,083232 claims |
| Johnson & JohnsonXarelto, Procrit | $34 | $230,962169 claims |
| AmgenNplate | $21 | $60,75912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 242 hematology & oncology providers in Maryland.
Other hematology & oncology in Elkton
- Robert KreitmanOlney$54.2M
- Ralph BocciaBethesda$12.1M
- Dan ZandbergBaltimore$9.9M
- Ani BalmanoukianBaltimore$6.6M
- Mark MarkowskiBaltimore$5.9M
- Giuseppe GiacconeBethesda$5.4M
- Ivana GojoBaltimore$5M
- Suman RaoBaltimore$4.2M
- Tim GretenBethesda$4.2M
- Patrick FordeBaltimore$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.